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Abstract
Aims: Cancer-related fatigue (CRF) is often accompanied by depressed mood,
both of which reduce functional status and quality of life. Research suggests
that increased expression of pro-inflammatory cytokines is associated with
skeletal muscle wasting and depressive- and fatigue-like behaviors in rodents
and cancer patients. We have previously shown that treatment with
ibuprofen, a nonsteroidal anti-inflammatory drug, preserved muscle mass in
tumor-bearing mice. Therefore, the purpose of the present study was to
determine the behavioral effects of ibuprofen in a mouse model of CRF.
Main methods: Mice were injected with colon-26 adenocarcinoma cells and
treated with ibuprofen (10 mg/kg) in the drinking water. Depressive-like
behavior was determined using the forced swim test (FST). Fatigue-like
behaviors were determined using voluntary wheel running activity (VWRA)
and grip strength. The hippocampus, gastrocnemius muscle, and serum were
collected for cytokine analysis.
Key findings: Tumor-bearing mice showed depressive-like behavior in the
FST, which was not observed in mice treated with ibuprofen. VWRA and grip
strength declined in tumor-bearing mice, and ibuprofen attenuated this
decline. Tumor-bearing mice had decreased gastrocnemius muscle mass and
increased expression of IL-6, MAFBx and MuRF mRNA, biomarkers of protein
degradation, in the muscle. Expression of IL-1β and IL-6 was also increased
in the hippocampus. Treatment with ibuprofen improved muscle mass and
reduced cytokine expression in both the muscle and hippocampus of tumorbearing mice.
Significance: Ibuprofen treatment reduced skeletal muscle wasting,
inflammation in the brain, and fatigue- and depressive-like behavior in tumorbearing mice. Therefore, ibuprofen warrants evaluation as an adjuvant
treatment for CRF.
Keywords: Fatigue, Depression, Cancer, Neuroinflammation, Ibuprofen
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1. Introduction
Fatigue is a common and disabling side effect of cancer and
cancer therapies. Cancer related fatigue (CRF) significantly reduces
quality of life1,2,3,4 and is frequently associated with depressed
mood.5,6,7 The mechanism for this association is unclear and is
relevant for development of effective treatments to reduce fatigue and
depression in cancer survivors.1
In response to tumor growth, increased expression of immune
mediators leads to systemic inflammation throughout the host.8 In
skeletal muscle, pro-inflammatory cytokines activate NF-κB, which
increases expression of proteins involved in muscle degradation,
including MAFbx and MuRF1.9,10 Tumor-bearing mice develop
extensive loss of muscle mass and show functional impairments such
as decreased grip strength11,12,13 and reduced voluntary wheel running
activity (VWRA).11 Fatigue is often the presenting complaint of newly
diagnosed cancer patients and sarcopenia can be present at the time
of diagnosis.14
Increased expression of pro-inflammatory cytokines is also
associated with depressed mood.15 In animal models of CRF, tumor
growth has been shown to increase inflammation within the brain.11,16
This is important because increases in brain interleukin (IL)-1β are
linked to both muscle atrophy17 and depressed mood11,15 in mice. In
addition, evidence from rodent models indicates that inflammatory
cytokines within the CNS are associated with behavioral symptoms of
fatigue, such as decreased VWRA activity.11,18,19
Inflammatory cytokines increase prostaglandin synthesis, an
important mediator of the inflammatory response. Common
nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen,
decrease prostaglandin synthesis by inhibiting the cyclo-oxygenase
(COX) enzymes and nitric oxide (NO).20 Ibuprofen has been shown to
decrease depressive-like behavior in a mouse model of bacterial
infection,21 and a recent clinical report showed decreased depression
scores in osteoarthritis patients treated with ibuprofen.22 Treatment
with NSAIDs has been shown to reduce skeletal muscle wasting in
tumor-bearing mice23,24,25 and to improve grip strength and
performance status in cancer patients treated with ibuprofen.26
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However, the effects of ibuprofen or other NSAIDs on CRF have not
been studied. Here, we examined the effects of ibuprofen on
depressive and fatigue-like behaviors in a mouse model of CRF. Using
this model, we have previously shown that tumor growth is associated
with increased muscle and brain expression of IL-1β and IL-6 mRNA,
increased serum levels of IL-6, skeletal muscle wasting and weakness,
and the development of fatigue- and depressive-like behaviors.11,27,28

2. Materials and methods
2.1. Mice
Adult (10 weeks) female BALB/c x DBA/2F1 (CD2F1) mice
weighing 20–22 g were obtained from Charles River Laboratories.
Female mice were used because we and others have shown that
tumor-bearing females maintain their food intake and lose a smaller
percent of body mass than male mice29 and male mice tend to gnaw
and bite at the tumor site, causing local inflammation.30 Mice were
singly housed and maintained at 25 °C under a 12 h light cycle with ad
libitum access to water and rodent chow. All procedures were
performed in accordance with the National Institute of Health
Guidelines for the Care and Use of Laboratory Animals and were
approved by The Ohio State University Institutional Animal Care and
Use Committee.

2.2. Mouse model of tumor-growth
The colon-26 adenocarcinoma (C26) cell line was maintained in
culture and prepared for injection as previously described.27,31 Half the
mice were injected subcutaneously between the scapulae with 5 × 105
cells in 0.2 ml of PBS, and half served as healthy controls with PBS
injection alone. This tumor cell line is syngeneic for CD2F1 mice and
secretes IL-6 and TNF-α25 and does not metastasize when injected
subcutaneously.32 Tumor growth is usually palpable by day 7, weight
loss, splenomegaly, and muscle wasting are evident after day 14, and
mice become moribund by day 24 of tumor-growth. In the present
study, all data collection was completed by day 21 of tumor growth.
Body weight was monitored three times a week for the first two
weeks, and daily during the third week. Mice were euthanized by
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inhalation of CO2 gas on day 21 of tumor growth. Gastrocnemius
muscles, spleen, and tumor were dissected and weighed; the brain
was quickly dissected and hippocampus brain tissue was snap frozen in
liquid nitrogen. Gastrocnemius weights were averaged and were
normalized to body weight. At the time of sacrifice, 3 tumor-vehicle
and 3 tumor-ibuprofen mice were removed from the study because
there was no tumor growth established.

2.3. Oral ibuprofen administration
Ibuprofen sodium salt (Sigma, St. Louis) was dissolved at
50 mg per liter (0.05 mg/mL) of filtered drinking water. Ibuprofen was
then administered in the drinking water of half the tumor-bearing and
half the healthy control mice starting three days after injection of PBS
or tumor cells. Based on water consumption of 4 mL per day, this
gives a dose of 10 mg/kg/day ibuprofen. A dose of 5 mg/kg has
previously been shown to decrease muscle wasting in C26 tumorbearing mice23 and a dose of 40 mg/kg has been shown to suppress
depressive-like behavior in mice inoculated with Bacillus Calmette–
Guerin (BCG).21 All other animals received water only (vehicle). Water
bottles were changed weekly throughout the study.

2.4. Voluntary wheel running activity
Fatigue-like behavior was modeled as decreased voluntary
wheel running activity (VWRA).33 Mice were singly housed and
acclimated to a four inch diameter running wheel in the cage for one
week, and baseline measures (week 0) of VWRA were recorded
overnight prior to injection with tumor cells or PBS. Wheels were again
placed in the home cages of all mice overnight (6 p.m. to 8 a.m.) on
days 7 (week 1), 14 (week 2) and 20 (week 3) of tumor growth and
the total number of turns each night was digitally recorded (Columbus
Instruments, model 0297-004M). Data are expressed as a percentage
of baseline.

2.5. Grip strength measurements
Forelimb grip strength was determined as previously
described.34 In brief, each mouse was allowed to grasp a platform with
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both forelimbs and was pulled by the tail until it released itself from
the platform (Columbus Instruments, model 1027DSM). Peak force
measurements (N) were recorded in five trials and the average was
calculated. Because smaller mice have smaller grip strength, peak
force was normalized to body weight of the animal.

2.6. Depressive-like behavior
Depressive-like behavior was determined on day 13 using the
forced swim test (FST) as described previously.35 In the FST, mice
were placed in an inescapable cylinder (diameter 16 cm, height 30 cm)
containing 15 cm of water and behavior was recorded for 5 min. The
latency to become immobile and the duration of immobility were
determined.

2.7. RNA isolation and RT-PCR analysis
Total RNA was isolated from hippocampus brain sections using
the Tri-Reagent protocol (Sigma) and reverse transcribed to cDNA
using the High Capacity cDNA Reverse Transcription kit (Applied
Biosystems). Quantitative PCR was performed using the Applied
Biosystems Assay-on-Demand Gene Expression protocol. In brief,
experimental cDNA was amplified with an ABI PRISM 7300-sequence
detection system (Applied Biosystems) by real-time PCR and
normalized based on reference cDNA (GAPDH). RNA was isolated from
the gastrocnemius muscle using a TissueLyser system in TRIzol
Reagent. RNA was extracted and purified using RNeasy spin column
purification (Qiagen, Valencia, CA.). RNA was reverse transcribed
using iScript Reverse Transcription Supermix (Bio-Rad, 175 Hercules,
CA) and quantitative PCR was performed using a three-step protocol
on the CFX96 Real 176 Time System (Bio-Rad), as described
previously.27 Briefly, cDNA was amplified using real time qPCR and was
normalized based on reference cDNA (GAPDH). All data were analyzed
with the comparative threshold cycle method. Data is expressed as
fold change from control-vehicle.
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2.8. Statistical analyses
Data were subjected to a Shapiro–Wilk test using Statistical
Analysis Systems (SAS) software (Cary, NC). Data were analyzed
using two-way ANOVA (tumor, drug) using the General Linear Model
procedures of SAS. When significant main or interaction effects were
found, post hoc analyses for differences between group means were
evaluated with the Least-Significant Difference procedure of SAS. All
data are expressed as treatment means ± standard error of the mean
(SEM).

3. Results
3.1. Ibuprofen ameliorated fatigue- and depressive-like
behaviors in tumor-bearing mice
Half the tumor-bearing and half the healthy control mice
received water (vehicle) or water containing ibuprofen starting three
days after tumor cell inoculation until study completion. Depressivelike behavior was determined at 13 days after tumor cell inoculation
using the forced swim test (FST). There was a main effect of ibuprofen
on time immobile (F1,38 = 7.64, p < 0.01), but no main effect of tumor.
As shown in Fig. 1A, tumor-bearing mice given water only (vehicle)
had increased total time immobile in the FST (p < 0.02), compared to
healthy control mice. Tumor-bearing mice treated with ibuprofen,
however, did not differ from control mice in total time immobile during
the FST. These data suggest ibuprofen mitigated depressive-like
behavior in the tumor-bearing mice.
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Fig. 1. Ibuprofen ameliorated fatigue- and depressive-like behaviors in tumor-bearing
mice. Control and tumor-bearing mice were treated with ibuprofen (10 mg/kg/day) in
the drinking water. A) Immobility in the forced swim test (FST) was determined on
day 13 of tumor growth. B) Voluntary wheel running activity (VWRA) was determined
before tumor cell injection and again at days 7, 14, and 20. Data are expressed as
percentage of baseline. Data were analyzed using two-way ANOVA and post hoc ttests for significant main effects: *p < 0.05 from control-vehicle, #p < 0.05 from
tumor-vehicle.

Fatigue-like behavior was determined using voluntary wheel
running activity (VWRA)33 prior to tumor cell inoculation and again at
7, 14, and 20 days of tumor growth. There was a main effect of tumor,
but not ibuprofen, on VWRA on day 20 (F1,43 = 13.78, p < 0.01) (Fig.
1B). Post hoc tests revealed that VWRA of vehicle treated tumorbearing mice was significantly decreased compared to vehicle-treated
control mice (p < 0.02). VWRA of tumor-bearing mice treated with
ibuprofen, however, was not significantly different from vehicle-treated
control mice (p = 0.09). These data suggest that ibuprofen blunted the
decline in VWRA in tumor-bearing mice.
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3.2. Ibuprofen improved grip strength in tumor-bearing
mice
Forelimb grip strength was determined prior to tumor cell
inoculation (week 0) and at 12 days and 19 days of tumor growth. Fig.
2A shows the absolute grip strength and Fig. 2B shows the grip
strength normalized to body weight. There was a main effect of tumor
growth on absolute grip strength at 19 days (F1,38 = 48.99, p < 0.01)
and a main effect of ibuprofen (F1,38 = 16.3, p < 0.01). Grip strength
of both vehicle and ibuprofen treated tumor-bearing mice was
decreased compared to control mice (p < 0.02). Grip strength in
tumor-bearing mice treated with ibuprofen, however, was greater than
vehicle treated tumor mice (p < 0.001). As shown in Fig. 2B,
normalized grip strength of vehicle treated tumor-bearing mice was
decreased compared to control mice (p < 0.001). Normalized grip
strength in tumor-bearing mice treated with ibuprofen, however was
not different from control mice (p = 0.11), indicating that ibuprofen
blunted the decline in grip strength in tumor-bearing mice.

Fig. 2. Ibuprofen restored grip strength in tumor-bearing mice. Control and tumorbearing mice were treated with ibuprofen (10 mg/kg/day) in the drinking water. A)
Absolute grip strength was determined before tumor cell injection and again at day 11
and 19. B) At day 20, grip strength was normalized to body weight. Data were
analyzed using two-way ANOVA and post hoc t-tests for significant main effects:
*p < 0.05 from control-vehicle, #p < 0.05 from tumor-vehicle.
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3.3. Ibuprofen decreased systemic inflammation in
tumor-bearing mice
After completion of behavioral testing on day 21, mice were
weighed, euthanized, and tumor, gastrocnemius, spleen, and brain
were collected. Tumor-bearing mice had increased spleen weight
(F1,38 = 87.49, p < 0.01), a nonspecific measure of systemic
inflammation induced by tumor growth.36 There was an interaction
between tumor and ibuprofen on spleen weight (F1,38 = 5.85,
p < 0.02). As shown in Fig. 3A, ibuprofen treatment reduced spleen
weight in the tumor-bearing mice (p < 0.003), although it remained
significantly greater than in control animals (p < 0.001). Tumorbearing mice also had increased plasma levels of IL-6 compared to
control animals (F1,25 = 14.37, p < 0.002). Ibuprofen tended to reduce
plasma IL-6 in tumor-bearing mice, though the difference between
tumor groups was not significant (p = 0.1) (Fig. 3B). As shown in Fig.
3C, tumor weight tended to be lower in ibuprofen treated mice,
although the difference was not significant (p = 0.3).

Fig. 3. Ibuprofen decreased systemic inflammation and muscle wasting in tumorbearing mice. Control and tumor-bearing mice were treated with ibuprofen
(10 mg/kg/day) in the drinking water. A) Spleen weight, B) plasma IL-6, C) tumor
mass, and D) gastrocnemius muscle mass was determined at day 21. Gastrocnemius
mRNA expression of E) MuRF, F) MAFBx, and G) IL-6 mRNA expression was
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determined at day 21. Data were analyzed using two-way ANOVA and post hoc t-tests
for significant main effects: *p < 0.05 from control-vehicle, #p < 0.05 from tumorvehicle.

3.4. Ibuprofen reduced muscle wasting in tumorbearing mice
There was a main effect of tumor growth on the relative
gastrocnemius muscle mass (F1,38 = 18.40, p < 0.001), and an
interaction effect of ibuprofen and tumor on muscle mass (F1,38 = 5.16,
p < 0.03). Post hoc analyses demonstrated that relative muscle mass
was decreased in tumor-bearing mice (p < 0.01) but that muscle mass
of tumor-bearing mice treated with ibuprofen was not different from
controls, consistent with our previous study23 (Fig. 3D). Because
ibuprofen preserved gastrocnemius muscle mass in the tumor-bearing
mice, we next determined mRNA expression of MuRF and MAFBx,
biomarkers of protein degradation, in the muscle. There was a main
effect of tumor on mRNA expression of MuRF (F1,38 = 6.94, p < 0.01).
However, post hoc analyses showed that MuRF expression in tumorbearing mice treated with ibuprofen was not different from control
mice (Fig. 3E). Similar to MuRF, there was a main effect of tumor
growth on mRNA expression of MAFBx (F1,38 = 6.28, p < 0.02). Post
hoc analyses showed that only the tumor-vehicle treated group, and
not the tumor-ibuprofen treated group, was significantly different from
controls (p < 0.006) (Fig. 3F). Thus, ibuprofen mitigated the effect of
tumor growth on muscle expression of MuRF and MAFBx, as previously
reported.23,24,25 Similarly, IL-6 mRNA expression was increased in
muscle of tumor-bearing mice (F1,38 = 13.97, p < 0.001), but there
was no significant effect of ibuprofen treatment (Fig. 3G). These data
indicate that ibuprofen treatment abrogated expression of MAFBx and
MuRF, biomarkers of muscle degradation in gastrocnemius muscle of
tumor-bearing mice, and this was associated with decreased muscle
wasting.

3.5. Ibuprofen attenuated neuroinflammation in tumorbearing mice
We have previously shown that tumor growth increased IL-1β
and IL-6 mRNA expression in the brain at 2 weeks of tumor growth
and that expression levels were further increased by 3 weeks.11 In the
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present study, tumor-bearing mice had increased expression of IL-1β
(F1,45 = 13.06, p < 0.01) and IL-6 (F1,45 = 5.83, p < 0.02) mRNA in
the hippocampus compared to controls at day 21 (Fig. 4A & B). There
was also a main effect of ibuprofen on IL-1β expression (F1,45 = 4.68,
p < 0.04), but there was no main effect of ibuprofen on IL-6
expression (p = 0.08). However, there was an interaction effect of
ibuprofen on IL-6 mRNA expression in the hippocampus of tumorbearing animals (F1,45 = 8.1, p < 0.01). These data suggest that
ibuprofen reduced expression of IL-1β in both tumor-bearing and
control mice, but selectively decreased IL-6 expression in the tumorbearing animals. Post hoc tests revealed that mRNA expression of IL1β in the tumor-vehicle mice was greater than in healthy controls,
while expression levels in the tumor-ibuprofen mice was not different
from controls and was significantly lower than the tumor-vehicle mice
(p < 0.02). Similarly, expression of IL-6 mRNA in the untreated tumor
mice was greater than in controls, and expression in the ibuprofen
treated tumor mice was not different from controls. Thus, ibuprofen
reduced neuroinflammation in the tumor-bearing mice.

Fig. 4. Ibuprofen attenuated neuroinflammation in tumor-bearing mice. Control and
tumor-bearing mice were treated with ibuprofen (10 mg/kg/day) in the drinking water.
On day 21, the brain was collected and the hippocampus was dissected. A) IL-1β and
B) IL-6 mRNA expression was determined. Data were analyzed using two-way ANOVA
and post hoc t-tests for significant main effects: *p < 0.05 from control-vehicle,
#
p < 0.05 from tumor-vehicle.
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4. Discussion
Many cancer patients suffer with a constellation of symptoms
termed cancer-related fatigue (CRF) which significantly impacts their
quality of life.37,38 To date, there are no effective therapies for CRF.
Moreover, CRF is often associated with depressed mood which also
lowers quality of life and increases morbidity and mortality in cancer
survivors.39,40 Both conditions are associated with increased expression
of pro-inflammatory cytokines.1,8,15,16 In the present study, we used a
mouse model of CRF in which tumor-bearing mice had increased
plasma levels of IL-6, depressive-like behaviors in the forced swim
test, decreased VWRA, and decreased muscle mass and grip strength.
Ibuprofen treatment reduced muscle wasting and inflammation within
the hippocampus of tumor-bearing mice. This is significant as the
hippocampus is a brain region involved in both mood and cognition.41
As a result, both fatigue- and depressive-like behaviors were
attenuated in the tumor-bearing mice treated with ibuprofen.
In our study, tumor-bearing mice had elevated levels of IL-6 in
the plasma. Mice treated with ibuprofen tended to have decreased
levels of IL-6 compared to vehicle treated mice, although IL-6 levels
remained elevated compared to control mice. These data suggest that
ibuprofen attenuated, but did not prevent, systemic inflammation,
compared to control mice. This observation is supported by the
increased spleen mass in tumor-bearing animals that was reduced by
treatment with ibuprofen, although spleen mass remained greater than
healthy control animals. It is possible that a higher dose of ibuprofen,
or different NSAIDs might further reduce systemic inflammation in the
tumor-bearing mice.
Pro-inflammatory cytokines increase expression of biomarkers
of autophagy and muscle protein degradation within muscle tissue,
which likely contributes to the loss of muscle mass and grip strength in
the tumor-bearing mice.9,42 We have previously shown that NSAID
treatment can reduce expression of mediators of degradation, such as
MAFBx and MuRF1, and reduce muscle wasting in tumor-bearing
mice.23,24,25 Here, we confirm that ibuprofen treatment abrogated
expression of MAFBx and MuRF mRNA in the muscle of in tumorbearing mice. However, we did not find that ibuprofen reduced
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expression of IL-6 in muscle tissue, again raising the question of dose
or alternative anti-inflammatory agents on tumor-induced muscle
wasting. It is also possible that muscle IL-6 does not play a major role
in muscle wasting. More importantly, the preservation of muscle mass
was associated with improved grip strength and a smaller decline in
VWRA in the tumor-bearing mice treated with ibuprofen.
In addition to their peripheral effects, tumor-induced cytokines
can activate the brain resident immune cells, microglia, which can
further propagate these inflammatory signals throughout the central
nervous system (CNS). This is critical as we have previously shown
that increased inflammation in the brains of tumor-bearing mice is
associated with both fatigue- and depressive like behaviors.19
Administration of minocycline, a broad spectrum antibiotic with antiinflammatory capacity, inhibited microglial activation in tumor-bearing
mice which resulted in reduced neuroinflammation and reduced
depressive-like behavior in tumor-bearing mice.11 Furthermore,
increased neuroinflammation is thought to induce depressive-like
behavior via increased activity of IDO and KMO, which may reduce
serotonin synthesis and availability in the brain.43,44 For example, we
have previously shown that treatment with the SSRI Fluoxetine
ameliorated depressive-like behavior in tumor bearing mice.19 Here we
show that ibuprofen decreased IL-1β and IL-6 mRNA expression in the
hippocampus of tumor-bearing mice to levels seen in healthy control
mice. Further research using methods such as microdialysis is needed
to determine if ibuprofen also restored serotonin levels in the
cerebrospinal fluid of treated versus untreated tumor-bearing mice.
Overall, the reduction in inflammation within the brains of tumorbearing mice treated with ibuprofen was associated with reduced
depressive-like behaviors determined using the forced swim test.
These data support other studies demonstrating that ibuprofen
reduces depressive mood associated with inflammatory conditions.21,22
In the present study, fatigue was modeled as reduced
VWRA.33,45 We demonstrated that ibuprofen treatment tended to
decrease this fatigue behavior in tumor-bearing mice. CRF may also
involve muscle weakness, which was modeled as decreased grip
strength. However, we have previously shown that grip strength can
be improved without improvement in muscle mass.11 Therefore, in the
present study, it is possible that improvement in these fatigue
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behaviors may have been influenced by both the reduction in
depressed mood and the rescue in muscle mass with ibuprofen
treatment.
In conclusion, we show beneficial effects of ibuprofen treatment
on skeletal muscle mass and fatigue- and depressive-like behaviors in
this mouse model of CRF. Previous clinical studies have shown
prolonged survival46 and improved grip strength and performance
status in cancer patients treated with NSAIDs.26 Our findings
presented here suggest that NSAID treatment could have beneficial
effects on muscle mass, physical performance, and mood of persons
with CRF.
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